← Back to Search

Virus Therapy

CoVLP formulation for COVID-19

Phase 3
Waitlist Available
Research Sponsored by Medicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female subjects must be 18 - 49 years of age at screening visit.
Subjects must have a body mass index < 35 kg/m2 at screening visit.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes after each vaccine administration
Awards & highlights

Study Summary

This study is evaluating whether there is consistency in the immunogenicity of three lots of Coronavirus-like Particle (CoVLP).

Eligible Conditions
  • COVID-19
  • Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~seven days following each vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and seven days following each vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
GMTs of the three vaccine lots
Secondary outcome measures
GMFRs
Immediate adverse events
Other adverse events
+3 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Group 3Experimental Treatment1 Intervention
CoVLP Lot 3
Group II: Group 2Experimental Treatment1 Intervention
CoVLP Lot 2
Group III: Group 1Experimental Treatment1 Intervention
CoVLP Lot 1

Find a Location

Who is running the clinical trial?

MedicagoLead Sponsor
18 Previous Clinical Trials
59,360 Total Patients Enrolled
3 Trials studying COVID-19
31,226 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Mar 2025